Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain Jun 08, 2016 7:00am EDT
Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure May 16, 2016 7:00am EDT
Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society May 11, 2016 4:30pm EDT
Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update May 05, 2016 7:00am EDT
Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine May 02, 2016 4:01pm EDT
Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference Apr 15, 2016 7:00am EDT
Trevena to Present at the Needham & Company 15th Annual Healthcare Conference Apr 07, 2016 7:00am EDT
Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting Mar 31, 2016 7:00am EDT
